Q-omics provides the consensus-scored SMIM34A profile across patient tissues and cancer cell-line models. SMIM34A expression is associated with patient survival in 11 of 34 cancer types, with the highest sampling consensus in CESC. Among the 18 cancer types available for tumor–normal comparison, SMIM34A is differentially expressed in 1, with the highest sampling consensus in KICH. Additionally, SMIM34A RNA expression shows 9,903 significant gene co-expression associations, with the highest sampling consensus in KIRC. Together, these results highlight CESC, KICH, and KIRC as cancer lineages where SMIM34A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SMIM34A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SMIM34A survival associations across molecular data types. SMIM34A RNA expression shows survival associations in the most cancer types (11). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SMIM34A RNA expression–survival associations across cancer types. High SMIM34A expression shows unfavorable associations in CESC, COAD, BLCA, OV, HNSC and SKCM. The CESC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify CESC as the clearest survival context for SMIM34A RNA expression.
This table summarizes SMIM34A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for SMIM34A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SMIM34A shows higher tumor expression in KICH. The KICH box plot shows higher SMIM34A RNA expression in tumor versus normal tissue (log2 FC = +0.043, t-test p = .019).
This table shows molecular features associated with SMIM34A in patient tissues and cancer cell lines. In patient samples, SMIM34A shows the broadest associations at the RNA and protein expression levels, with KIRC recurring as the lineage with the largest associated feature set. In cancer cell lines, SMIM34A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in CNS.
